ERBB2 and non-small cell lung carcinoma: While DESTINY-Lung01 and DESTINY-Lung02 are single-armed studies, it is apparent that HER2-mutated NSCLC patients would likely experience superior outcomes when treated with TDXd compared to an alternative standard of care [89,91,92,98].